Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Non-Current Assets (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Non-Current Assets for 14 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets changed N/A year-over-year to $1.0 million, compared with a TTM value of $3.1 million through Sep 2025, up 154350.0%, and an annual FY2023 reading of $2000.0, down 99.98% over the prior year.
  • Non-Current Assets was $1.0 million for Q3 2025 at Alaunos Therapeutics, up from $997000.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.4 million in Q2 2021 and bottomed at $2000.0 in Q4 2023.
  • Average Non-Current Assets over 4 years is $9.8 million, with a median of $11.1 million recorded in 2022.
  • The sharpest move saw Non-Current Assets surged 136.7% in 2021, then plummeted 99.98% in 2023.
  • Year by year, Non-Current Assets stood at $16.0 million in 2021, then plummeted by 30.54% to $11.1 million in 2022, then tumbled by 99.98% to $2000.0 in 2023, then skyrocketed by 51850.0% to $1.0 million in 2025.
  • Business Quant data shows Non-Current Assets for TCRT at $1.0 million in Q3 2025, $997000.0 in Q2 2025, and $1.1 million in Q1 2025.